Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$34.88
Change (%) Stock is Up 0.17 (0.49%)
Volume625,211
Data as of 10/16/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
10/05/17The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2017
–VABOMERE was associated with higher overall cure and lower mortality versus “best available therapy” in subjects with known or suspected carbapenem-resistant Enterobacteriaceae (CRE)– –VABOMERE was also associated with better safety and significantly better overall risk-benefit than best available therapy– PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 5, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that new data from it... 
Printer Friendly Version
09/28/17The Medicines Company to Present Data at IDWeek 2017 on Infectious Disease Portfolio Including Recently Approved Antibiotic VABOMERE™ (meropenem and vaborbactam)
– Eight posters presented on Friday and Saturday highlight comprehensive results of TANGO-2, a multi-center, randomized, open label clinical trial of VABOMERE vs. "best available therapy" in subjects with known or suspected CRE – – VABOMERE was recently approved for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis, caused by designated susceptible Enterobacteriacea – PARSIPPANY, N.J.--(B... 
Printer Friendly Version
08/30/17The Medicines Company Announces FDA Approval of VABOMERE™ (meropenem and vaborbactam)
–Accelerated approval for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis– –First carbapenem-based combination product – combination of meropenem with a new class of beta-lactamase inhibitor– –Addresses pathogens designated by the CDC as urgent and serious antimicrobial resistance threats, and pathogens cited by the WHO as a critical need for new antibiotics– –VABOMERE exp... 
Printer Friendly Version
08/28/17New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials
–Inclisiran lowering effects on bad-cholesterol (LDL-C) are robust (mean 56% at Day-150; maximum 81%) and sustained (average 51% across a planned six-month dosing interval), with minimum intra-patient variability– –Safety data for inclisiran from ORION-1 now include 370 subject-years of observation, including at least 300 subject-years of inclisiran effects; no material safety issues observed on inclisiran – similar to placebo– ... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.